Does the media favor IRTC or BVS?

In the previous week, iRhythm Technologies had 7 more articles in the media than Bioventus. MarketBeat recorded 10 mentions for iRhythm Technologies and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.22 beat iRhythm Technologies' score of 0.85 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, BVS or WRBY?

Bioventus has higher earnings, but lower revenue than Warby Parker. Bioventus is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.74 $22.73M $0.41 28.78 Warby Parker $890.57M 2.95 $1.64M $0.02 1,226.25

Is BVS or WRBY more profitable?

Bioventus has a net margin of 4.94% compared to Warby Parker's net margin of 0.15%. Bioventus' return on equity of 29.97% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% Warby Parker 0.15% 2.30% 1.18%

Does the media prefer BVS or WRBY?

In the previous week, Bioventus had 1 more articles in the media than Warby Parker. MarketBeat recorded 3 mentions for Bioventus and 2 mentions for Warby Parker. Bioventus' average media sentiment score of 1.22 beat Warby Parker's score of 0.71 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Warby Parker 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ESTA or BVS?

Bioventus has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $229.58M 11.83 -$51.06M -$1.49 N/A Bioventus $568.09M 1.74 $22.73M $0.41 28.78

Does the media favor ESTA or BVS?

In the previous week, Establishment Labs had 3 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Establishment Labs and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.22 beat Establishment Labs' score of 1.11 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TMDX or BVS?

TransMedics Group has higher revenue and earnings than Bioventus. TransMedics Group is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $635.89M 3.93 $190.29M $4.40 16.42 Bioventus $568.09M 1.74 $22.73M $0.41 28.78

Does the media favor TMDX or BVS?

In the previous week, TransMedics Group had 6 more articles in the media than Bioventus. MarketBeat recorded 9 mentions for TransMedics Group and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.22 beat TransMedics Group's score of 1.02 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BVS or LMAT?

In the previous week, Bioventus and Bioventus both had 3 articles in the media. LeMaitre Vascular's average media sentiment score of 1.77 beat Bioventus' score of 1.22 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Bioventus (BVS) Competitors

$11.80 +0.32 (+2.79%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$11.80 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

BVS vs. IRTC, WRBY, ESTA, TMDX, and LMAT

Should you buy Bioventus stock or one of its competitors? MarketBeat compares Bioventus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventus include iRhythm Technologies (IRTC), Warby Parker (WRBY), Establishment Labs (ESTA), TransMedics Group (TMDX), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.

How does Bioventus compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Bioventus (NASDAQ:BVS) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

62.9% of Bioventus shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by company insiders. Comparatively, 33.5% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bioventus has a net margin of 4.94% compared to iRhythm Technologies' net margin of -3.53%. Bioventus' return on equity of 29.97% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Bioventus	4.94%	29.97%	9.52%

iRhythm Technologies has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

iRhythm Technologies currently has a consensus price target of $184.71, suggesting a potential upside of 69.15%. Bioventus has a consensus price target of $14.75, suggesting a potential upside of 25.00%. Given iRhythm Technologies' higher probable upside, equities analysts clearly believe iRhythm Technologies is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.80	-$44.55M	-$0.86	N/A
Bioventus	$568.09M	1.74	$22.73M	$0.41	28.78

In the previous week, iRhythm Technologies had 7 more articles in the media than Bioventus. MarketBeat recorded 10 mentions for iRhythm Technologies and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.22 beat iRhythm Technologies' score of 0.85 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bioventus beats iRhythm Technologies on 9 of the 16 factors compared between the two stocks.

How does Bioventus compare to Warby Parker?

Bioventus (NASDAQ:BVS) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Bioventus currently has a consensus price target of $14.75, suggesting a potential upside of 25.00%. Warby Parker has a consensus price target of $29.82, suggesting a potential upside of 21.58%. Given Bioventus' stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bioventus has a net margin of 4.94% compared to Warby Parker's net margin of 0.15%. Bioventus' return on equity of 29.97% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Warby Parker	0.15%	2.30%	1.18%

62.9% of Bioventus shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 16.8% of Warby Parker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bioventus has higher earnings, but lower revenue than Warby Parker. Bioventus is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.74	$22.73M	$0.41	28.78
Warby Parker	$890.57M	2.95	$1.64M	$0.02	1,226.25

In the previous week, Bioventus had 1 more articles in the media than Warby Parker. MarketBeat recorded 3 mentions for Bioventus and 2 mentions for Warby Parker. Bioventus' average media sentiment score of 1.22 beat Warby Parker's score of 0.71 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Warby Parker	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Warby Parker has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

Summary

Bioventus beats Warby Parker on 11 of the 17 factors compared between the two stocks.

How does Bioventus compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Bioventus (NASDAQ:BVS) are both medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Bioventus has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$229.58M	11.83	-$51.06M	-$1.49	N/A
Bioventus	$568.09M	1.74	$22.73M	$0.41	28.78

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 33.5% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bioventus has a net margin of 4.94% compared to Establishment Labs' net margin of -19.05%. Bioventus' return on equity of 29.97% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Bioventus	4.94%	29.97%	9.52%

In the previous week, Establishment Labs had 3 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Establishment Labs and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.22 beat Establishment Labs' score of 1.11 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Establishment Labs currently has a consensus price target of $90.43, indicating a potential downside of 2.05%. Bioventus has a consensus price target of $14.75, indicating a potential upside of 25.00%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Bioventus beats Establishment Labs on 12 of the 17 factors compared between the two stocks.

How does Bioventus compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Bioventus (NASDAQ:BVS) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

TransMedics Group presently has a consensus price target of $134.50, indicating a potential upside of 86.13%. Bioventus has a consensus price target of $14.75, indicating a potential upside of 25.00%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, TransMedics Group had 6 more articles in the media than Bioventus. MarketBeat recorded 9 mentions for TransMedics Group and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.22 beat TransMedics Group's score of 1.02 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has higher revenue and earnings than Bioventus. TransMedics Group is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$635.89M	3.93	$190.29M	$4.40	16.42
Bioventus	$568.09M	1.74	$22.73M	$0.41	28.78

TransMedics Group has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

TransMedics Group has a net margin of 27.04% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Bioventus	4.94%	29.97%	9.52%

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

TransMedics Group beats Bioventus on 10 of the 17 factors compared between the two stocks.

How does Bioventus compare to LeMaitre Vascular?

Bioventus (NASDAQ:BVS) and LeMaitre Vascular (NASDAQ:LMAT) are both medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

LeMaitre Vascular has a net margin of 24.35% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
LeMaitre Vascular	24.35%	15.36%	9.78%

In the previous week, Bioventus and Bioventus both had 3 articles in the media. LeMaitre Vascular's average media sentiment score of 1.77 beat Bioventus' score of 1.22 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

62.9% of Bioventus shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LeMaitre Vascular has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.74	$22.73M	$0.41	28.78
LeMaitre Vascular	$249.60M	8.75	$57.73M	$2.71	35.27

Bioventus currently has a consensus target price of $14.75, indicating a potential upside of 25.00%. LeMaitre Vascular has a consensus target price of $112.60, indicating a potential upside of 17.79%. Given Bioventus' stronger consensus rating and higher probable upside, equities analysts plainly believe Bioventus is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

Bioventus has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Summary

LeMaitre Vascular beats Bioventus on 9 of the 16 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVS vs. The Competition

Export

Metric	Bioventus	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$958.98M	$3.03B	$7.24B	$12.25B
Dividend Yield	N/A	N/A	40.99%	9.79%
P/E Ratio	28.78	21.41	23.62	23.71
Price / Sales	1.74	254.21	160.98	73.79
Price / Cash	9.00	8.66	165.01	59.64
Price / Book	4.28	5.32	12.77	6.07
Net Income	$22.73M	$23.43M	$120.21M	$331.84M
7 Day Performance	-2.16%	-4.53%	-0.94%	-1.53%
1 Month Performance	21.27%	-8.21%	-1.97%	-2.46%
1 Year Performance	79.60%	2.17%	9.83%	13.66%

Bioventus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVS Bioventus	4.4271 of 5 stars	$11.80 +2.8%	$14.75 +25.0%	+84.4%	$958.98M	$568.09M	28.78	1,200	News Coverage
IRTC iRhythm Technologies	4.1632 of 5 stars	$110.88 -3.9%	$186.62 +68.3%	-17.5%	$3.64B	$787.85M	N/A	2,400	News Coverage Analyst Upgrade
WRBY Warby Parker	3.3995 of 5 stars	$26.46 -4.1%	$29.82 +12.7%	+0.7%	$2.95B	$871.91M	1,323.81	4,036
ESTA Establishment Labs	2.0371 of 5 stars	$92.58 +0.3%	$90.43 -2.3%	+114.0%	$2.72B	$211.08M	N/A	1,004	News Coverage Positive News
TMDX TransMedics Group	4.7073 of 5 stars	$73.98 -2.7%	$134.50 +81.8%	-32.3%	$2.63B	$605.49M	16.81	210	News Coverage Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BVS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Competitors

BVS vs. IRTC, WRBY, ESTA, TMDX, and LMAT

How does Bioventus compare to iRhythm Technologies?

Summary

How does Bioventus compare to Warby Parker?

Summary

How does Bioventus compare to Establishment Labs?

Summary

How does Bioventus compare to TransMedics Group?

Summary

How does Bioventus compare to LeMaitre Vascular?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Competitors

BVS vs. IRTC, WRBY, ESTA, TMDX, and LMAT

How does Bioventus compare to iRhythm Technologies?

Do insiders and institutionals hold more shares of IRTC or BVS?

Is IRTC or BVS more profitable?

Which has more volatility & risk, IRTC or BVS?

Do analysts prefer IRTC or BVS?

Which has higher valuation & earnings, IRTC or BVS?

Does the media favor IRTC or BVS?

Summary

How does Bioventus compare to Warby Parker?

Do analysts prefer BVS or WRBY?

Is BVS or WRBY more profitable?

Do insiders & institutionals have more ownership in BVS or WRBY?

Which has better valuation & earnings, BVS or WRBY?

Does the media prefer BVS or WRBY?

Which has more risk and volatility, BVS or WRBY?

Summary

How does Bioventus compare to Establishment Labs?

Which has higher valuation & earnings, ESTA or BVS?

Do institutionals & insiders believe in ESTA or BVS?

Is ESTA or BVS more profitable?

Does the media favor ESTA or BVS?

Which has more risk & volatility, ESTA or BVS?

Do analysts prefer ESTA or BVS?

Summary

How does Bioventus compare to TransMedics Group?

Do analysts rate TMDX or BVS?

Does the media favor TMDX or BVS?

Which has preferable earnings and valuation, TMDX or BVS?

Which has more risk and volatility, TMDX or BVS?

Is TMDX or BVS more profitable?

Do insiders & institutionals believe in TMDX or BVS?

Summary

How does Bioventus compare to LeMaitre Vascular?

Is BVS or LMAT more profitable?

Does the media refer more to BVS or LMAT?

Do insiders and institutionals believe in BVS or LMAT?

Which has stronger valuation and earnings, BVS or LMAT?

Do analysts rate BVS or LMAT?

Which has more volatility and risk, BVS or LMAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools